search
Back to results

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients (REVOLUTION)

Primary Purpose

Lung Transplant; Complications

Status
Recruiting
Phase
Phase 3
Locations
Netherlands
Study Type
Interventional
Intervention
Extended release tacrolimus
Immediate release tacrolimus
Sponsored by
Heleen Grootjans
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Transplant; Complications focused on measuring lung transplantation, chronic kidney disease, cardiovascular disease, extended release tacrolimus, LCP tacrolimus, immediate release tacrolimus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent
  • Single or bilateral lung transplantation
  • On twice daily tacrolimus with stable trough levels in target range
  • Participant in the TransplantLines biobank study in the UMCG

Additional criteria for Conversion cohort:

  • At least one year after lung transplantation with a stable clinical course and lung function
  • eGFR >30ml/min*1.73m2 calculated with the CKD-EPI formula

Exclusion Criteria:

  • Administration of mTOR inhibitors; everolimus, sirolimus
  • Quadruple immunosuppression
  • Renal transplantation
  • The subject has any disease or condition that might interfere with completion of this study or reaching the primary endpoint (e.g., life expectancy of <3 years, renal replacement therapy at start study)

Sites / Locations

  • University medical center GroningenRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

de novo cohort, extended release tacrolimus

de novo cohort, immediate release tacrolimus

conversion cohort, extended release tacrolimus

conversion cohort, immediate release tacrolimus

Arm Description

de novo cohort, extended release tacrolimus

de novo cohort, immediate release tacrolimus

conversion cohort, extended release tacrolimus

conversion cohort, immediate release tacrolimus

Outcomes

Primary Outcome Measures

renal function: absolute change in eGFR
absolute change in eGFR absolute change in eGFR change in eGFR at 2 years

Secondary Outcome Measures

graft function
Acute graft dysfunction is a clinical diagnoses, with or without histological confirmation, and indictation for rejection treatment such as methylprednisolon. Chronic graft dysfunction is defined according to the ISHLT guidelines, as a persistent decline (≥20%) in measured FEV1 value from baseline.
renal function: 40% eGFR reduction
40% eGFR reduction
renal function: 50% eGFR reduction
50% eGFR reduction
renal function:end stage kidney disease
end stage kidney disease
hypertension
Incidence of inadequate regulated or new onset of hypertension
diabetes mellitus
Incidence of inadequate glycemic control of preexisting diabetes mellitus or new onset diabetes after transplantation (NODAT)
Infections
Incidence of infections
Malignancies
Incidence of malignancies
neurological function: tremor
Incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin (FTM) tremor rating scale (grades of tremor 0-4, in which 0 indicated no tremor and 4 severe tremor)
neurological function: polyneuropathy
Incidence of or change in pre-existing polyneuropathy
neurological function: sleep quality
Incidence of or change in sleep quality by using validated questionnaire: Pittsburg Sleep Quality Index (PSQI)
neurological function: cognitive functioning
Incidence of or change in cognitive functioning by using validated questionnaire: the Cognitive Functioning Questionnaire (CFQ)
quality of life score
change in SF36 score
pharmacogenetic
explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus renal toxicity by using absolute eGFR change
pharmacogenetic
explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus neurological toxicity: change in incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin tremor rating scale

Full Information

First Posted
July 1, 2021
Last Updated
May 9, 2023
Sponsor
Heleen Grootjans
Collaborators
Chiesi Farmaceutici S.p.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT05001074
Brief Title
Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients
Acronym
REVOLUTION
Official Title
Randomized Controlled Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 28, 2020 (Actual)
Primary Completion Date
August 1, 2024 (Anticipated)
Study Completion Date
August 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Heleen Grootjans
Collaborators
Chiesi Farmaceutici S.p.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Lung transplantation is a life-saving option in patients with end-stage lung disease. The introduction of calcineurin inhibitors has significantly improved long-term outcome in lung transplantation. The most frequently used calcineurin inhibitor as maintenance therapy is immediate release tacrolimus, dosed twice daily, which has shown to reduce both acute and chronic rejection. However, a drawback to the administration of tacrolimus is its toxicity. Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the high cardiovascular burdon in this patient group. Since a few years an once daily extended release tacrolimus has been introduced in solid organ transplantation. The advantage of extended release tacrolimus is its prolonged release and higher bioavailability than other tacrolimus formulations. This result in lower peaks, more stable serum levels over 24 hours, and less fluctuation of blood concentrations. Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo and stable post-lung transplant recipients should be investigated.
Detailed Description
Lung transplantation is a life-saving option in patients with end-stage lung disease. The introduction of calcineurin inhibitors (CNI) has significantly improved long-term outcome in lung transplantation. The most frequently used CNI as maintenance therapy is immediate release tacrolimus, dosed twice daily, which has shown to reduce both acute and chronic rejection. However, a drawback to the administration of tacrolimus is its toxicity. Especially progressive renal toxicity, new onset diabetes and hypertension contribute to the high cardiovascular burdon in this patient group. In lung transplant recipients the incidence of severe renal impairment, new onset of diabetes mellitus, hypertension and dyslipidemia is 53,9%, 40%, 80% and 40,3% post lung transplantation. Tremor is one of the most common CNI induced neurological toxic effect, besides polyneuropathy, headaches, insomnia, vertigo, dysesthesia and reduced cognitive ability. These complications are, among others, attributed to high peak serum tacrolimuslevels, whereas the effectiveness of the drug is determined by the area under the curve. In general lung transplant recipients have higher peak and trough levels when compared to other solid organ transplant recipients and therefore potentially experience more severe toxic side effects. Since a few years an once daily extended release tacrolimus has been introduced in solid organ transplantation. The advantage of extended release tacrolimus is its prolonged release and higher bioavailability than other tacrolimus formulations. This result in lower peaks, more stable serum levels over 24 hours, and less fluctuation of blood concentrations. In addition, for an equal overall systemic tacrolimus exposure a 30% lower dosage is needed for extended release tacrolimus when compared to other formulations. In kidney and liver transplantation, extended release tacrolimus is safe and effective. Langone et al demonstrated in an enriched population of kidney transplant patients with tremor, that extended release tacrolimus improved hand tremor compared to immediate release tacrolimus. Long-term toxicity outcome of extended release tacrolimus after lung transplantation has not been studied so far. Therefore the potential benefit of exteded release tacrolimus in de novo and stable post-lung transplant recipients should be investigated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Transplant; Complications
Keywords
lung transplantation, chronic kidney disease, cardiovascular disease, extended release tacrolimus, LCP tacrolimus, immediate release tacrolimus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
De novo cohort, 2 arms: de novo lung transplant recipients. Conversion cohort, 2 arms: stable lung transplant recipients
Masking
None (Open Label)
Allocation
Randomized
Enrollment
145 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
de novo cohort, extended release tacrolimus
Arm Type
Experimental
Arm Description
de novo cohort, extended release tacrolimus
Arm Title
de novo cohort, immediate release tacrolimus
Arm Type
Active Comparator
Arm Description
de novo cohort, immediate release tacrolimus
Arm Title
conversion cohort, extended release tacrolimus
Arm Type
Experimental
Arm Description
conversion cohort, extended release tacrolimus
Arm Title
conversion cohort, immediate release tacrolimus
Arm Type
Active Comparator
Arm Description
conversion cohort, immediate release tacrolimus
Intervention Type
Drug
Intervention Name(s)
Extended release tacrolimus
Other Intervention Name(s)
LCP tacrolimus
Intervention Description
de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when >1 year post-lungtransplantation and with stable graft function
Intervention Type
Drug
Intervention Name(s)
Immediate release tacrolimus
Intervention Description
de novo cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus direct post-lung transplantation Conversion cohort: participants are randomised for extended release tacrolimus or immediate release tacrolimus when >1 year post-lungtransplantation and with stable graft function
Primary Outcome Measure Information:
Title
renal function: absolute change in eGFR
Description
absolute change in eGFR absolute change in eGFR change in eGFR at 2 years
Time Frame
2 years
Secondary Outcome Measure Information:
Title
graft function
Description
Acute graft dysfunction is a clinical diagnoses, with or without histological confirmation, and indictation for rejection treatment such as methylprednisolon. Chronic graft dysfunction is defined according to the ISHLT guidelines, as a persistent decline (≥20%) in measured FEV1 value from baseline.
Time Frame
2 years
Title
renal function: 40% eGFR reduction
Description
40% eGFR reduction
Time Frame
2 years
Title
renal function: 50% eGFR reduction
Description
50% eGFR reduction
Time Frame
2 years
Title
renal function:end stage kidney disease
Description
end stage kidney disease
Time Frame
2 years
Title
hypertension
Description
Incidence of inadequate regulated or new onset of hypertension
Time Frame
2 years
Title
diabetes mellitus
Description
Incidence of inadequate glycemic control of preexisting diabetes mellitus or new onset diabetes after transplantation (NODAT)
Time Frame
2 years
Title
Infections
Description
Incidence of infections
Time Frame
2 years
Title
Malignancies
Description
Incidence of malignancies
Time Frame
2 years
Title
neurological function: tremor
Description
Incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin (FTM) tremor rating scale (grades of tremor 0-4, in which 0 indicated no tremor and 4 severe tremor)
Time Frame
2 years
Title
neurological function: polyneuropathy
Description
Incidence of or change in pre-existing polyneuropathy
Time Frame
2 years
Title
neurological function: sleep quality
Description
Incidence of or change in sleep quality by using validated questionnaire: Pittsburg Sleep Quality Index (PSQI)
Time Frame
2 years
Title
neurological function: cognitive functioning
Description
Incidence of or change in cognitive functioning by using validated questionnaire: the Cognitive Functioning Questionnaire (CFQ)
Time Frame
2 years
Title
quality of life score
Description
change in SF36 score
Time Frame
2 years
Title
pharmacogenetic
Description
explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus renal toxicity by using absolute eGFR change
Time Frame
2 years
Title
pharmacogenetic
Description
explorative endpoints: effects of well known variances in CYP3A4, CYP3A5 and ABCB1 transporter function on tacrolimus metabolism (resulting in so-called slow and fast tacrolimus metabolisers) on long-term tacrolimus neurological toxicity: change in incidence of or change in pre-existing hand tremor by using the validated Fahn-Tolosa-Martin tremor rating scale
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent Single or bilateral lung transplantation On twice daily tacrolimus with stable trough levels in target range Participant in the TransplantLines biobank study in the UMCG Additional criteria for Conversion cohort: At least one year after lung transplantation with a stable clinical course and lung function eGFR >30ml/min*1.73m2 calculated with the CKD-EPI formula Exclusion Criteria: Administration of mTOR inhibitors; everolimus, sirolimus Quadruple immunosuppression Renal transplantation The subject has any disease or condition that might interfere with completion of this study or reaching the primary endpoint (e.g., life expectancy of <3 years, renal replacement therapy at start study)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Heleen Grootjans
Phone
0031503616161
Email
h.grootjans@umcg.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Tji Gan
Phone
0031503616161
Email
c.t.gan@umcg.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tji Gan
Organizational Affiliation
University Medical Center Groningen
Official's Role
Principal Investigator
Facility Information:
Facility Name
University medical center Groningen
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heleen Grootjans
Phone
0031503616161
First Name & Middle Initial & Last Name & Degree
Tji Gan
First Name & Middle Initial & Last Name & Degree
Heleen Grootjans
First Name & Middle Initial & Last Name & Degree
Erik Verschuuren
First Name & Middle Initial & Last Name & Degree
Stefan Berger
First Name & Middle Initial & Last Name & Degree
Daan Touw

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29965950
Citation
Sintes H, Saez-Gimenez B, Berastegui C, Lopez-Meseguer M, Monforte V, Bravo C, Vima J, Gomez-Olles S, Roman A. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. Transplantation. 2018 Oct;102(10):e439-e446. doi: 10.1097/TP.0000000000002348.
Results Reference
result
PubMed Identifier
24492423
Citation
Mendez A, Berastegui C, Lopez-Meseguer M, Monforte V, Bravo C, Blanco A, Camos S, Pou L, Roman A. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. Transplantation. 2014 Feb 15;97(3):358-62. doi: 10.1097/01.TP.0000435699.69266.66.
Results Reference
result
PubMed Identifier
25707487
Citation
TruneCka P, Klempnauer J, Bechstein WO, Pirenne J, Friman S, Zhao A, Isoniemi H, Rostaing L, Settmacher U, Monch C, Brown M, Undre N, Tisone G; DIAMONDdagger study group. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. Am J Transplant. 2015 Jul;15(7):1843-54. doi: 10.1111/ajt.13182. Epub 2015 Feb 23.
Results Reference
result
PubMed Identifier
31815310
Citation
Sanchez Fructuoso A, Ruiz JC, Franco A, Diekmann F, Redondo D, Calvino J, Serra N, Aladren MJ, Cigarran S, Manonelles A, Ramos A, Gomez G, Gonzalez Posada JM, Andres A, Beneyto I, Muniz AL, Perello M, Lauzurica R. Effectiveness and safety of the conversion to MeltDose(R) extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study. Clin Transplant. 2020 Jan;34(1):e13767. doi: 10.1111/ctr.13767. Epub 2019 Dec 31.
Results Reference
result

Learn more about this trial

Trial Comparing Immediate Versus Extended Release Tacrolimus; Reducing Calcineurin Inhibitor Related Toxicity in Lung Transplantation Patients

We'll reach out to this number within 24 hrs